GB201816547D0 - Oncolytic virus for the treatment of cancer - Google Patents

Oncolytic virus for the treatment of cancer

Info

Publication number
GB201816547D0
GB201816547D0 GBGB1816547.2A GB201816547A GB201816547D0 GB 201816547 D0 GB201816547 D0 GB 201816547D0 GB 201816547 A GB201816547 A GB 201816547A GB 201816547 D0 GB201816547 D0 GB 201816547D0
Authority
GB
United Kingdom
Prior art keywords
cancer
treatment
oncolytic virus
oncolytic
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1816547.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary University of London filed Critical Queen Mary University of London
Priority to GBGB1816547.2A priority Critical patent/GB201816547D0/en
Publication of GB201816547D0 publication Critical patent/GB201816547D0/en
Priority to US17/284,169 priority patent/US12509704B2/en
Priority to KR1020217013839A priority patent/KR20210102196A/ko
Priority to PCT/GB2019/052877 priority patent/WO2020074902A1/en
Priority to CN201980081698.5A priority patent/CN113453713A/zh
Priority to EP19794623.9A priority patent/EP3863669A1/en
Priority to JP2021519114A priority patent/JP7410139B2/ja
Priority to CA3123973A priority patent/CA3123973A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1816547.2A 2018-10-10 2018-10-10 Oncolytic virus for the treatment of cancer Ceased GB201816547D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB1816547.2A GB201816547D0 (en) 2018-10-10 2018-10-10 Oncolytic virus for the treatment of cancer
US17/284,169 US12509704B2 (en) 2018-10-10 2019-10-10 Oncolytic vaccinia virus with modified B5R gene for the treatment of cancer
KR1020217013839A KR20210102196A (ko) 2018-10-10 2019-10-10 암 치료를 위한 변형된 b5r 유전자를 갖는 종양용해 백시니아 바이러스
PCT/GB2019/052877 WO2020074902A1 (en) 2018-10-10 2019-10-10 Oncolytic vaccinia virus with modified b5r gene for the treatment of cancer
CN201980081698.5A CN113453713A (zh) 2018-10-10 2019-10-10 用于治疗癌症的具有修饰的b5r基因的溶瘤痘苗病毒
EP19794623.9A EP3863669A1 (en) 2018-10-10 2019-10-10 Oncolytic vaccinia virus with modified b5r gene for the treatment of cancer
JP2021519114A JP7410139B2 (ja) 2018-10-10 2019-10-10 癌治療のための修飾ｂ５ｒ遺伝子を有する腫瘍溶解性ワクシニアウイルス
CA3123973A CA3123973A1 (en) 2018-10-10 2019-10-10 Oncolytic vaccinia virus with modified b5r gene for the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1816547.2A GB201816547D0 (en) 2018-10-10 2018-10-10 Oncolytic virus for the treatment of cancer

Publications (1)

Publication Number Publication Date
GB201816547D0 true GB201816547D0 (en) 2018-11-28

Family

ID=64397608

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1816547.2A Ceased GB201816547D0 (en) 2018-10-10 2018-10-10 Oncolytic virus for the treatment of cancer

Country Status (7)

Country Link
EP (1) EP3863669A1 (enExample)
JP (1) JP7410139B2 (enExample)
KR (1) KR20210102196A (enExample)
CN (1) CN113453713A (enExample)
CA (1) CA3123973A1 (enExample)
GB (1) GB201816547D0 (enExample)
WO (1) WO2020074902A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3262167A1 (en) * 2022-07-27 2024-02-01 Astrazeneca Ab COMBINATIONS OF RECOMBINATING VIRUSES EXPRESSING INTERLEUKIN-12 WITH PD-1/PDL1 INHIBITORS
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405834D0 (en) * 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
US10888594B2 (en) * 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
TW201825674A (zh) * 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒

Also Published As

Publication number Publication date
KR20210102196A (ko) 2021-08-19
JP2022502066A (ja) 2022-01-11
CA3123973A1 (en) 2020-04-16
JP7410139B2 (ja) 2024-01-09
US20210332384A1 (en) 2021-10-28
WO2020074902A1 (en) 2020-04-16
CN113453713A (zh) 2021-09-28
EP3863669A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
IL295609B1 (en) Hemisulfate nucleotide salt for treatment of hepatitis c virus
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
IL253243A0 (en) Combined preparations for the treatment of cancer or infection
IL285221A (en) Use of oncolytic viruses to treat cancer
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
IL278618B2 (en) Cancer treatment
EP3134423A4 (en) 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
IL280468A (en) Secondary vaccine particles for cancer treatment
EP3875119A4 (en) ONCOLYTIC VIRUS FOR CANCER THERAPY
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
GB201803197D0 (en) Viral treatment
GB201816547D0 (en) Oncolytic virus for the treatment of cancer
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
IL281782A (en) Drug combination for cancer treatment
HK40062440A (en) Use of oncolytic viruses for the treatment of cancer
HK40041691A (en) Treatment using oncolytic virus
HK40005971A (en) Phosphoramidates for the treatment of hepatitis b virus
HK40019139A (en) Oncolytic virus therapy
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
GB201713936D0 (en) Pharmaceutical combinations for the treatment of cancer
HK40006685A (en) Dihydropyranopyrimidines for the treatment of viral infections

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)